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Plasmodium falciparum, the most deadly agent of malaria, displays a wide variety of resistance mechanisms in the field. The
ability of antimalarial compounds in development to overcome these must therefore be carefully evaluated to ensure uncompro-
mised activity against real-life parasites. We report here on the selection and phenotypic as well as genotypic characterization of
a panel of sensitive and multidrug-resistant P. falciparum strains that can be used to optimally identify and deconvolute the
cross-resistance signals from an extended panel of investigational antimalarials. As a case study, the effectiveness of the selected
panel of strains was demonstrated using the 1,2,4-oxadiazole series, a newly identified antimalarial series of compounds with in
vitro activity against P. falciparum at nanomolar concentrations. This series of compounds was to be found inactive against sev-
eral multidrug-resistant strains, and the deconvolution of this signal implicated pfcrt, the genetic determinant of chloroquine
resistance. Targeted mode-of-action studies further suggested that this new chemical series might act as falcipain 2 inhibitors,
substantiating the suggestion that these compounds have a site of action similar to that of chloroquine but a distinct mode of
action. New antimalarials must overcome existing resistance and, ideally, prevent its de novo appearance. The panel of strains
reported here, which includes recently collected as well as standard laboratory-adapted field isolates, is able to efficiently detect
and precisely characterize cross-resistance and, as such, can contribute to the faster development of new, effective antimalarial
drugs.
Since the beginning of this century, the revived interest of theinternational community in the control of malaria, together
with the 2007 call for an eradication agenda, resulted in a signifi-
cant decrease in the burden of mortality andmorbidity associated
with this parasitic disease (2–4). Over the past 12 years, the global
malaria mortality rate has decreased by an estimated 45%, avert-
ing 3.3 million deaths, 90% of which were among children under
5 years of age in sub-Saharan Africa (7). This has been achieved, at
least in part, by the increased availability of safe and efficacious
antimalarial chemotherapies. In 2012, 331 million courses of ar-
temisinin-based combination therapies (ACTs), recommended
by the WHO for first-line treatment of uncomplicated Plasmo-
dium falciparummalaria, were delivered to the public and private
sectors (7). However, in the absence of a fully protective antima-
larial vaccine, the development and spread of drug resistance by P.
falciparum are likely to constitute serious obstacles to the eradica-
tion of malaria.
The ability of P. falciparum to develop resistance mechanisms
had a major impact on the efficacy of two former mainstay thera-
pies for uncomplicatedmalaria, chloroquine and the sulfadoxine-
pyrimethamine combination, whose use for the curative treat-
ment of infections caused by this species had to be abandoned (11,
12). Before then, the prolonged use of partially ineffective chloro-
quine treatments in sub-Saharan Africa is reported to have caused
an increase in malaria mortality of up to 3-fold (14).
ACTs are now threatened by the emergence of P. falciparum
strains with reduced sensitivity to artesunate, a phenotype that
was first reported in Southeast Asia in 2008 and that has spread
locally since then (16–18). Failures of artesunate-mefloquine
treatment and, more recently, dihydroartemisinin-piperaquine
treatment have been reported in areas of artemisinin resistance
(19–23). This suggests that the therapeutic efficacy of ACT might
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be compromised, which is a major concern, considering that no
alternative treatments are ready to be deployed (25).
Resistance to essentially all antimalarial drugs previously or
currently used to treat P. falciparummalaria have been identified
to various degrees and levels of geographical spread (6). More-
over, resistance to new antimalarial compounds currently in clin-
ical development can often be selected for in vitro, demonstrating
the genetic ability of P. falciparum to acquire resistance to these
compounds and suggesting that none would be intrinsically re-
fractory to resistance if they happened to be deployed as new an-
timalarial therapies (27–29). Thus, measures need to be taken at
all stages of the drug development process to minimize liabilities
due to resistance and to maximize the life span over which anti-
malarial therapies have efficacy.
The Medicines for Malaria Venture (MMV) is a not-for-profit
organization with the mission to discover, develop, and facilitate
the delivery of new, effective, and affordable antimalarial drugs
(31). Recently, a semiquantitative in vitro framework was devel-
oped to evaluate the resistance liabilities of new antimalarials and
is currently used in MMV’s collaborative projects to identify and
deprioritize compounds for which the risk of the development of
resistance is overt early in development (15). The underlying
strategy is 2-fold: first, to evaluate if new antimalarial compounds
show cross-resistance with previously or currently marketed
antimalarials, as evidenced by a loss of in vitro activity due to
mechanisms of resistance known to operate in natural parasite
populations, and second, to evaluate the propensity of de novo
mechanisms of resistance to new compounds to be selected in
vitro. The first goal is achieved bymeasuring the in vitro activity of
compounds against a panel of standard sensitive and multidrug-
resistant (MDR) strains which were selected to represent strains
with the major resistance mechanisms known to operate in the
field (15). In this study, we deployed this selected panel of strains
to determine if they accurately displayed the intended resis-
tance phenotypes, effectively identified signs of cross-resis-
tance to new antimalarial compounds, and allowed the decon-
volution of the determinants of the cross-resistance signals. We
present and discuss the use of this approach for the detailed
evaluation of the cross-resistance of a new antimalarial chem-
ical series identified by high-throughput compound screening.
MATERIALS AND METHODS
Plasmodium falciparum strain culture and drug assays. P. falciparum
strains NF54, D6, HB3, FCB, 7G8, K1, Dd2, and V1/S were obtained from
theMalaria Research andReferenceReagentResourceCenter (MR4;www
.mr4.org). Strain TM90C2B was provided by Dennis E. Kyle (University
of South Florida). These strainsweremaintained in vitrousing themethod
of Trager and Jensen (35). Parasite growth after exposure to serial dilu-
tions of antimalarial compounds was assessed using the [3H]hypoxan-
thine incorporation assay, and the level of inhibition of growth is ex-
pressed as the median (50%) inhibitory concentration (IC50) (36, 37).
Exposures of 72 h were performed to allow the detection of slow-acting
compounds and to enhance data reproducibility (38).
Themulticlonal parasite linesHL1210 andHL1212were isolated from
patients presenting to the Hospital for Tropical Diseases in London,
United Kingdom, in 2012 after returning from travel to Ghana and Nige-
ria, respectively, and are described in detail elsewhere (30). Both strains
originated from areas of endemicity where ACT has been in use since the
mid-2000s and thus likely have prior exposure to lumefantrine, dihydro-
artemisinin, and potentially other ACT partner drugs. These strains were
maintained in vitro, and drug assays were performed as described in ref-
erence 30. These lines have been made publicly available at the European
Malaria Reagent Repository (http://www.malariaresearch.eu/).
Plasmodium falciparum sequencing. DNA for sequencing was ob-
tained from 10ml of nonsynchronized cultures at approximately 5% par-
asitemia. Cells were spun down, the pellet was lysed with 0.5% saponin,
and the parasites were subsequently spun down and lysed in the lysis
buffer contained in the Qiagen DNA purification kit. Nested PCRs were
set up for the gene domains in question using the primers listed in Table
S1 in the supplemental material and the conditions indicated in the Ma-
terials and Methods section in the supplemental material. PCR products
were cleaned using a Qiagen PCR cleanup kit and sent to Macrogen
(Amsterdam, The Netherlands) for bidirectional sequencing using the
same primers used for the nested reaction. All sequences were aligned
with the strain 3D7 reference sequences, and single nucleotide poly-
morphisms were called only if they were present on both strands.
pfmdr1 copy numbers were determined by real-time PCR as described
previously (39).
Synthesis and characterization of compounds 1, 2, and 3. The syn-
thesis and characterization of compounds 1, 2, and 3 of the 1,2,4-oxadia-
zole series are presented in the Materials and Methods section in the
supplementalmaterial. Compound 3was synthesized in a limited amount
and could not be included in all experiments reported here.
Saccharomyces cerevisiae heterologous system. DFR1, the gene en-
coding dihydrofolate reductase (DHFR) from Saccharomyces cerevisiae
(ScDHFR), was PCR amplified from genomic DNA templates and cloned
into pCM188 to generate pCMScDHFR (5). The DHFR-coding sequence
from Plasmodium falciparum (PfDHFR) with a codon usage suitable for
expression in yeast was synthesized by Geneart and was subcloned into
pCM188 (1) to generate pCMPfDHFR (5). The DHFR mutations N51I,
C59R, and S108N, which confer resistance to antifolates in wild Plasmo-
dium falciparum populations, were introduced by site-directed muta-
genesis into pCMPfDHFR to generate pCMPfRdhfrN51I, C59R,
pCMPfRdhfrS108N, and pCMPfRdhfrN51I, C59R, S108N. pCM constructs
were transformed into aBY4743-derived strain (pdr5::HisMX/PDR5dfr1::
KanMX/DFR1 MATa/MAT his31/his31 leu20/leu20 met150/
MET15 LYS2/lys20 ura30/ura30), and following sporulation and tet-
rad dissections, spores with the genotype pdr5::HIS3MX dfr1::KanMX
MAT his31 leu20MET15 lys20 ura30/pCMwere selected for use in
drug sensitivity assays.
Standard yeast growth conditions and either YPD (2% peptone, 1%
yeast extract, 2% glucose), supplemented sporulation medium (1% po-
tassium acetate, 0.1% yeast extract, 0.05% glucose, amino acid supple-
ments, 2% Bacto agar), or YNB-glucose (0.68% yeast nitrogen base, 2%
ammonium sulfate, 2% glucose, 0.015% leucine) were used for all assays.
Serial dilutions (5 times) of stationary-phase cultureswere prepared in
96-well plates and replicated onto YNB-glucose agar plates with or with-
out drugs. Cells were allowed to grow for 24 h at 30°C and then photo-
graphed.
In vitro hemozoin formation and falcipain 2 enzyme activity assays.
Falcipain 2 activity in the presence of compounds 1 and 2 and chloroquine
(5 M) was assessed using a fluorometric assay, where the release of
7-amino-4-methyl coumarin (AMC) wasmonitored (excitation, 355 nm;
emission, 460 nm) over 30 min at room temperature using an LS50B
Perkin-Elmer fluorimeter in a buffer containing 100 mM sodium acetate,
pH 5.5, 10 mM dithiothreitol, 7 M fluorogenic substrate Z-Phe-Arg-
AMC, and 200 nM enzyme. Falcipain 2 activity in the absence of any drug
was taken as a positive control. Details on the enzyme expression and
hemozoin formation assays are presented in the Materials and Methods
section in the supplemental material.
In vitro abiotic -hematin formation assay. The -hematin forma-
tion inhibition assay method described by Carter and colleagues was
modified for manual liquid delivery (8, 9). Solutions of the samples in
dimethyl sulfoxide were incubated in 96-well plates with NP-40 detergent
(30.55 M) and hematin (100 M) in an acetate buffer (1 M, pH 4.8) for
5 to 6 h at 37°C. The detection of free heme was based on the pyridine-
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ferrichrome method developed by Ncokazi and Egan (10). The detailed
assay procedure has been reported previously (13).
RESULTS
Genotypic validation of selected P. falciparum strains. The se-
lected panel of P. falciparum strains included the MDR strains
HB3, FCB, 7G8, K1, Dd2, V1/S, and TM90C2B as well as the
sensitive strains NF54 and D6, all of which were selected on the
basis of genotypic and phenotypic information previously re-
ported in the literature (15).
In order to evaluate the ability of these strains to identify cross-
resistance signals, genes involved in drug resistance were se-
quenced to confirm the presence of specific mutations known to
cause resistance to various antimalarial compounds (Table 1).
These genes were those for the P. falciparum chloroquine resis-
tance transporter (pfcrt), multidrug resistance 1 (pfmdr1), dihy-
drofolate reductase (pfdhfr), dihydropteroate synthase (pfdhps),
and cytochrome b (pfcytb). Mutations of pfcrt and pfmdr1 have
been shown to mediate resistance to chloroquine and amodi-
aquine, mutations of pfdhfr have been shown to mediate resis-
tance to pyrimethamine and cycloguanil, mutations of pfdhps
have been shown to mediate resistance to sulfadoxine, and muta-
tions of pfcytb have been shown to mediate resistance to atova-
quone. The expected pfcrt and pfcytb genotypes were observed,
and minor differences from the mutations reported in the litera-
ture were observed for pfmdr1, pfdhfr, and pfdhps (see the refer-
ences in reference 15). Regarding pfmdr1, strainHB3was found to
carry the mutation Y184F, while this residue was expected to be
wild type; strainDd2 had themutationN86F instead ofN86Y, and
strain 7G8 had themutation S1034R instead of S1034C. Four cop-
ies of the pfmdr1 gene (instead of two) and three copies of the
pfmdr1 gene (instead of four) were identified in strains FCB and
Dd2, respectively. FCB was also found to express the pfdhfrmuta-
tion A16T instead of A16V. Finally, strains NF54, HB3, and 7G8
were found to carry the pfdhps mutation S436F instead of the
wild-type residue.
Phenotypic validation of selected P. falciparum strains. The
presence of the expected resistance phenotypes in the panel of
strains was determined by measuring their sensitivity to various
standard antimalarial compounds during an in vitro exposure of
72 h. Artesunate, atovaquone, chloroquine, cycloguanil, meflo-
quine, and pyrimethamine were evaluated, and resistance was
considered to occur if themedian (50%) inhibitory concentration
(IC50) of a given strain was found to be, on average, more than
10-fold greater than that of the sensitive reference strain NF54
(Fig. 1; see Table S2 in the supplementalmaterial). This threshold,
which is only of an indicative nature, was selected to be in the
range of the smallest IC50 shifts associated with clinical resistance
(e.g., for chloroquine [40]), while it simultaneously avoided a
false-positive resistance signal due to the intrinsic variation of
phenotypic assays.
None of the strains tested showed resistance, as defined here, to
artesunate and mefloquine. As expected, TM90C2B was the only
strain resistant to atovaquone. NF54, D6, HB3, and 7G8 were
found to be sensitive to chloroquine; however, the phenotype of
7G8 was close to the resistance threshold, with 7G8 having an
8.3-fold greater tolerance to the drug than N54. FCB, K1, Dd2,
V1/S, and TM90C2B all displayed resistance to chloroquine. All
strains except NF54, D6, and HB3 were found to be resistant to
cycloguanil, while resistance to pyrimethaminewas apparent in all
strains except NF54, D6, and FCB. The selected strains effectively
displayed various resistance phenotypes and therefore represent
an appropriate tool for evaluating the potential cross-resistance of
antimalarial compounds with a variety of existing molecular
mechanisms of resistance.
Case study with the 1,2,4-oxadiazole series. To further evalu-
ate the ability of the selected panel of strains to identify and facil-
itate the characterization of cross-resistance signals from new an-
timalarial compounds, we studied three analogue compounds
(compounds 1, 2, and 3). These three molecules comprise a 1,2,4-
oxadiazole moiety, a 1,4-diazepam amide, a tertiary piperidine,
and an amide group, and we commonly refer to them as the
“1,2,4-oxadiazole” series (Fig. 2A). Compounds 1 and 2 were ini-
tially identified as hits on the erythrocytic stage of P. falciparum
during the phenotypic screening of a library of more than 250,000
compounds (24). Compound 3 was synthesized while performing
the resynthesis of compounds 1 and 2. The IC50s for these three
TABLE 1 Amino acid sequences of selected gene polymorphisms involved in P. falciparum drug resistance
Strain
Amino acid at the indicated position in the following genea:
pfcrt pfmdr1b pfdhfr pfdhps
pfcytb,
26872 73 74 75 76 86 184 1034 1042 1246 16 51 59 108 164 436 437 581 613
Wild type C V M N K N Y S N D A N C S I S A A A Y
NF54 C V M N K N Y S N D A N C S I F G A A Y
D6 C V M N K N Y S N D A N C S I A A A A Y
HB3 C V M N K N F S D D A N C N I F A A A Y
FCB C V I E T Y Y S N D T N C T I F A A A Y
7G8 S V M N T N F R D Y A I C N I F G A A Y
K1 C V I E T Y Y S N D A N R N I S G G A Y
Dd2 C V I E T F Y S N D A I R N I F G A S Y
V1/S C V I E T Y Y S N D A I R N L F G A T Y
TM90C2B C V I E T N F S N D A I R N L F G G A S
HL1210c C V I E T Y F S N D A I R N I S G A A n/a
HL1212c C V M N K N F S N D A I R N I S G A A n/a
a Mutant residues are shaded.
b The pfmdr1 copy number was 1 for the wild-type strain and strains NF54, D6, HB3, 7G8, K1, V1/S, TM90C2B, HL1210, and HL1212; 4 for FCB; and 3 for Dd2.
c As reported in reference 30.
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compounds tested against the sensitive strain NF54 ranged from
60 nM to 278 nM (Table 2). This, together with favorable physi-
cochemical properties, suggested that this novel chemical scaffold
might be a valuable starting point for a hit-to-lead medicinal
chemistry program. As part of a standard resistance risk assess-
ment and as a first filter, the activity of these compounds against
multidrug-resistant strain K1 was measured. A strong resistance
signal was identified, with theK1 IC50s ranging from3.8Mto 7.5
M, representing, for each compound, an increase in the IC50 of
more than 20-fold compared to the values forNF54 (Table 2). The
activity of these compounds was further profiled using the com-
plete panel ofP. falciparum strainswith the objective of identifying
the mechanism of resistance responsible for this loss of potency
against K1.
The relative activity of compounds 1, 2, and 3 against the panel
of strains is reported in Fig. 2B (absolute values are given in Table
S3 in the supplemental material). All three compounds were
found to be active against D6 and HB3. Compounds 1 and 2 were
inactive against all the other strains tested, that is, FCB, 7G8, K1,
Dd2, V1/S, and TM90C2B. Compound 3 displayed a similar lack
of activity against these strains, with the exception of 7G8, for
which the IC50 increased by only 7-fold. The overall profiles of
resistance to the three compounds were very similar. First, the D6
IC50 was slightly elevated; second, a further decrease in activity
against 7G8 and Dd2, resulting in resistance, as defined here, ex-
cept for the activity against 7G8 in the case of compound 3 was
detected; and finally, a complete loss of activity against the re-
maining strains (FCB, K1, V1/S, and TM90C2B) was found.
Compared to the resistance profiles obtained with standard
FIG 1 Phenotypic validation of the panel ofMDR strains. The relative IC50s of
artesunate (ART), atovaquone (ATO), chloroquine (CHQ), cycloguanil
(CYC), mefloquine (MEF), and pyrimethamine (PYR) against the panel of P.
falciparum laboratory strains are shown. The solid line shows a 10-fold in-
crease in the IC50 relative to that for NF54 (n 2; error bars are SDs).
FIG 2 Resistance profile of the 1,2,4-oxadiazole series. (A) Structures of the
three compounds from the 1,2,4-oxadiazol series. Ph, phenyl; Bn, benzyl; Me,
methyl. (B) Relative IC50s of compounds 1, 2, and 3 against a panel of P.
falciparum laboratory strains. The solid line shows a 10-fold increase in the
IC50 relative to that for NF54 (n 2; error bars are SDs).
TABLE 2 Activity of the 1,2,4-oxadiazole series compounds against the
NF54 and K1 P. falciparum strains
Compound
IC50 (nM)
a
Ratio of IC50 for
K1/IC50 for NF54NF54 K1
Chloroquine 10 157 16
1 60 4,972 83
2 163 3,813 23
3 278 7,465 27
a Values are from one representative experiment.
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antimalarials, the 1,2,4-oxadiazole series appeared to be cross-
resistant with two compounds, chloroquine and cycloguanil, sug-
gesting that genetic determinants of resistance to this series might
be mutations in pfcrt and pfdhfr. All the strains fully sensitive to
this series of compounds carry a wild-type pfcrt allele, whereas the
CVIET or SVMNT mutants displayed an elevated IC50 that was
beyond our threshold of resistance in the vast majority of cases.
Similarly, all resistant strains contained at least two mutations at
pfdhfr codon 16, 51, 59, 108, or 164, while the sensitive ones were
either wild type (NF54, D6) or contained only a single S108N
mutation (HB3). Conversely, no correlation between specificmu-
tations of pfmdr1, pfdhps, and pfcytb or copy number variations of
pfmdr1 and the sensitivity of specific strains to members of the
1,2,4-oxadiazole series was apparent.
In order to further discriminate between the pfcrt and pfdhfr
mutations as potential determinants for resistance to compounds
1, 2, and 3, their activity was evaluated in a heterologous system of
Saccharomyces cerevisiae strains expressing wild-type or mutated
versions of the P. falciparum dhfr gene (1). The growth of yeast
strains expressing S. cerevisiae dhfr (ScDHFR), the wild-type P.
falciparum dhfr (PfDHFR), or the mutant alleles PfdhfrN51I, C59R,
PfdhfrS108N, and PfdhfrN51I, C59R, S108N was determined in the pres-
ence of compounds 1, 2, and 3 and cycloguanil (see Fig. S1 in the
supplemental material). Cycloguanil specifically inhibited the
growth of yeast strains expressing the wild-type PfDHFR enzyme,
and this effect was partially lost with the PfdhfrN51I, C59R and
PfdhfrS108N alleles and totally lost with the triple mutant,
PfdhfrN51I, C59R, S108N. On the other hand, compounds 1, 2, and 3 failed
to inhibit the growth of the yeast strain expressing PfDHFR, and
no difference between strains expressing wild-type or mutated
versions of PfDHFR was noticeable. These data suggest the ab-
sence of cross-resistance between cycloguanil and the 1,2,4-ox-
adiazole series and appear to rule out dhfrmutations as the genetic
determinants of resistance to members of this chemical series ob-
served.
We next reasoned that if resistance to the 1,2,4-oxadiazole se-
ries was mediated by pfcrt mutations, it might be reversed by ve-
rapamil, similar to the findings for chloroquine resistance (26).
We exposed the pfcrtmutant and chloroquine-resistant strain K1
to either 0, 50, or 100 ng/ml of verapamil and determined the IC50
of artesunate (negative control), chloroquine (positive control),
and compounds 1, 2, and 3 under these conditions (see Fig. S2 in
the supplemental material). As expected, the sensitivity of K1 to
chloroquine, but not to artesunate, increased in a dose-dependent
manner with concomitant incubation with verapamil. The IC50s
of compounds 1 and 2 did not change in response to verapamil.
The sensitivity of strain K1 to compound 3 increased in response
to incubation with verapamil at concentrations of 50 ng/ml and
100 ng/ml, but to an extent lower than that for chloroquine (the
IC50s obtained by incubation with 100 ng/ml verapamil decreased
by 29% and 51% compared to those with no verapamil for com-
pound 3 and chloroquine, respectively).
The fact that verapamil did not significantly sensitize K1 to the
1,2,4-oxadiazole series suggests that pfcrt might not be the prime
genetic determinant of resistance to this series. An alternative hy-
pothesis is that the level of resistance to these compounds is too
high to be reversed by verapamil. The IC50s of compounds 1, 2,
and 3 for strain K1 ranged from 3.0 M to 11.0 M, whereas the
IC50 of chloroquine for K1was 1 order ofmagnitude lower, at 0.12
M. The relative shift in the IC50 compared to the NF54 IC50 was
also less for chloroquine, at 16-fold, whereas it was 74-, 43-, and
38-fold for compounds 1, 2, and 3, respectively. Alternatively,
higher verapamil concentrations might be required to induce a
reversion of the resistance of the pfcrt mutant parasites to the
1,2,4-oxadiazole series.
To evaluate the implication of pfcrtmutations in the resistance
to this chemical series in amore directmanner, we took advantage
of P. falciparum field isolates recently adapted to laboratory cul-
ture and fully characterized for key determinants of resistance
(30). More particularly, we selected isolates HL1210 and HL1212,
which share the same pfdhfr triple mutation haplotype and differ
in their pfcrt sequences. HL1210 is a pfcrt mutant (CVIET), and
HL1212 is a pfcrt wild-type strain (CVMNK) (Table 1). The chlo-
roquine IC50 observed for these two strains confirmed the resis-
tance and sensitivity status of HL1210 and HL1212, respectively
(Table 3). Both strains were equally susceptible to artesunate and
resistant to pyrimethamine and cycloguanil, as expected. The ac-
tivity of the 1,2,4-oxadiazole series mirrored that of chloroquine
rather than that of the DHFR inhibitors pyrimethamine and cy-
cloguanil, with a 60-fold or greater increase in activity against pfcrt
wild-type strain HL1212 than pfcrt mutant HL1210 (Table 3).
These results suggest that mutated PfCRTmight play a direct role
in P. falciparum resistance to the 1,2,4-oxadiazole series and, by
extension, that the mode of action of these compounds could
reside in the digestive vacuole, from which mutant forms of the
PfCRT transmembrane transporter are postulated to exclude
chloroquine in resistant parasites (32, 33).
The mode of action of chloroquine has been linked with the
inhibition of proteases involved in the degradation of hemoglobin
as well as with the prevention of hemozoin formation, possibly via
heme binding, in the digestive vacuole (see Fig. S3A in the supple-
mentalmaterial) (34). In order to evaluate if compounds from the
1,2,4-oxadiazole series might also interfere with the hemoglobin
degradation pathway, we measured the activity of compounds 1
and 2 in an in vitro hemozoin formation assay based on enzymatic
or autocatalytic reactions (see Fig. S3B to D and Table S4 in the
supplemental material). In vitro, heme can be released from he-
moglobin by falcipain 2 and subsequently converted to hemozoin
by the heme detoxification protein (HDP) or via an autocatalytic
mechanism (34, 41). The autocatalytic formation of hemozoin
appears to be slightly inhibited by compounds 1 and 2 (IC50s, 452
Mand 587M, respectively, compared to an IC50 of 43.5Mfor
amodiaquine; see Table S4 in the supplemental material). Prein-
TABLE 3 Sensitivity of recently laboratory-adapted P. falciparum
isolates to the 1,2,4-oxadiazole series compounds
Compound
IC50 (nM)
a Ratio of IC50 for
HL1210/IC50 for
HL1212HL1210 HL1212
Chloroquine 150.0 7.0 12.0 3.0 12.5
Artesunate 4.2 1.1 7.1 1.2 0.6
Pyrimethamine 10,000.0 10,000.0 NAb
Cycloguanil 879.0 218.0 1,877.0 156.0 0.5
1 2,270.0 548.0 33.0 10.0 68.8
2 2,694 502.0 44.0 11.0 61.3
3 10,000.0 98.0 26.0 100
a Data are means and standard errors of the means from at least five independent
experiments.
b NA, not applicable.
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cubation of HDP with compounds 1 and 2 did not inhibit the
formation of hemozoin (see Fig. S3B in the supplemental mate-
rial). However, the activity of falcipain 2 appeared to be markedly
inhibited by compounds 1 and 2 (5 M) in a fluorometric cata-
lytic assay; in contrast, chloroquine did not have any effect on
falcipain 2 activity per se (see Fig. S3C in the supplemental mate-
rial). In addition, to assess the effect of compounds 1 and 2 on the
released heme, they were added to a hemoglobin-to-hemozoin
conversion assay. The addition of either compound did not alter
the percentage of hemozoin formation, in contrast to chloro-
quine, which bound free heme and blocked hemozoin formation
(see Fig. S3D in the supplemental material). Altogether, these ob-
servations suggest that compounds of the 1,2,4-oxadiazole series
might be competitive inhibitors of the cysteine protease falcipain
2, a mode of action distinct from that of chloroquine but similarly
located in the food vacuole, and thus, the findings are in line with
a potential mode of resistance mediated by pfcrt.
A test cascade for resistance deconvolution. In order to ob-
tain themaximumamount of information about potential in vitro
cross-resistance mechanisms, a given set of strains should ideally
provide the highest level of resistance specificity. In other words, it
is desirable to occupy the maximum possible number of intersec-
tions when representing resistance to standard antimalarial com-
pounds as spaces in a Venn diagram (Fig. 3A). Such a graphical
representation illustrates that the combination of identical pfdhfr
sequences and divergent pfcrt sequences was absent from the se-
lected panel of standard P. falciparum laboratory strains and that
this combination is needed to resolve cases of resistance implicat-
ing strains with mutations in both these genes, as is the case with
compounds 1, 2, and 3. This limitation was circumvented by the
addition of HL1210 and HL1212 to the panel.
On the basis of the genotypic and phenotypic data reported
here, it is possible to devise an optimal deconvolution scheme that
allows acquisition of the maximum amount of information by
testing a minimal number of strains (Fig. 3B). At least one strain
from each intersection represented in Fig. 3A was included in this
scheme. Applying this signal deconvolution to the 1,2,4-oxadia-
zole series readily identified pfcrt to be a potential genetic deter-
minant of the resistance associated with this series. More gener-
ally, compounds active against Dd2 as well as TM90C2B are likely
to be pan-active, whereas a resistance signal forDd2 should trigger
the sequential testing of additional strains in order to provide
information about the potential genetic determinants of resis-
tance.
DISCUSSION
The genotypic and phenotypic evaluation of a panel of sensitive
andMDR P. falciparum strains previously selected to evaluate the
cross-resistance potential of antimalarial compounds is reported
here. Minor genotypic differences from those reported in the lit-
erature were identified for some residues of pfmdr1, pfdhfr, and
pfdhps and also for the pfmdr1 copy number. It is unknown
whether the sequences reported here are the original haplotypes of
these strains or if mutations were acquired during culture pas-
sages. Regardless, these are unlikely to significantly alter the re-
spective resistance phenotypes of these strains.
Indeed, the phenotype-based resistance profiles correlatedwell
with expectations on the basis of the findings in the literature as
well as with genotypic data. All strains carrying a mutant pfcrt
allele at codons 72 to 76 displayed in vitro resistance to chloro-
quine, according to our definition, with the exception of strain
7G8, the IC50 for which shifted by only 8.3-fold, as expected due to
the South American-type (SVMNT) mutant allele of this strain,
whereas the other mutant strains carries the Southeast Asian-type
FIG 3 Cross-resistance deconvolution. (A) Venn diagram of the profiles of resistance of the P. falciparum strains to atovaquone (ATO), chloroquine (CHQ),
cycloguanil (CYC), and pyrimethamine (PYR). The main genetic determinants of resistance for each compound is indicated, and the strains in boxes with bold
borders correspond to the ones evaluated in the assay whose results are presented in panel B. (B) Deconvolution cascade of cross-resistance signals determined
using the multidrug-resistant P. falciparum strain panel. R, resistant; S, sensitive; CNV, copy number variation.
Antimalarial Cross-Resistance Deconvolution
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allele (CVIET) (42). The SVMNThaplotype is best described as an
amodiaquine-resistant genotype, known to impart some survival
advantage after chloroquine treatment in vivo, but it does not lead
to IC50 estimates as high as those due to the CVIET formof pfcrt in
gene replacement studies (32). Strain TM90C2B was resistant to
atovaquone and was the only strain with a Y268S mutation in
PfCYTB. The responses to the DHFR inhibitors pyrimethamine
and cycloguanil were also in line with the observed pfdhfr se-
quences. The strains that had wild-type sequences at codons 16,
51, 59, 108, and 164 (ANCSI), strains NF54 andD6, were sensitive
to both compounds. Strains with the N51I, C59R, and S108N
triple mutations, that is, strains K1, Dd2, V1/S, and TM90C2B,
showed resistance to both compounds. Themutantwith the single
S108N mutation, HB3, showed resistance to pyrimethamine and
not to cycloguanil, while the conversewas true for themutantwith
the single S108T mutation, FCB. The pfdhps-mediated resistance
to sulfadoxine was not evaluated here because of the specific cul-
ture conditions required (43); however, it is expected, on the basis
of the pfdhps sequence diversity in specific resistance-mediating
residues, that cross-resistance with sulfonamides would be readily
and specifically identifiable by using the panel of strains under
appropriate culture conditions.
In this study, we defined resistance to be a greater than 10-fold
shift in the IC50 compared to the IC50 for strainNF54. This thresh-
old was arbitrary but small enough to be in line with the smallest
IC50 shifts documented to be associated with clinical resistance
and simultaneously large enough to avoid false-positive signals
due to assay variations. An IC50 shift of that magnitude should be
a cause for concern, warranting further investigations, such as the
ones described here for the 1,2,4-oxadiazole series. The attempt to
define more precisely drug-specific in vitro IC50 thresholds di-
rectly applicable to clinical situations is a challenging task for rea-
sons described elsewhere (44). We favor a simpler and more
conservative approach that is more relevant to antimalarial com-
pounds in development for which no clinical data exist.
We have reported on a new antimalarial chemical series, the
1,2,4-oxadiazole series, to whichMDR strain K1 was overtly resis-
tant. Importantly, no analogues of these compounds could be
found in the literature, and no hypothesis on their mode of action
could bemade. The complete profiling of three analogues with the
panel of strains suggested that the resistance of P. falciparum to
these compounds is likely to be mediated by pfcrt or pfdhfr. Fur-
ther independent experimental approaches seem to favor a role of
pfcrt over a role of pfdhfr but suggest that the mode of action of
these compounds is different from that of chloroquine. In partic-
ular, the addition of P. falciparum isolates recently adapted for
laboratory culture to the panel was necessary to provide further
segregation between resistance mediated by pfcrt and that medi-
ated by pfdhfr, revealing a shortcoming in the ability of the original
panel of strains to fully deconvolute cross-resistance signals. These
two isolates are also evolutionarily closer to the current target
parasite populations than the standard laboratory strains, most of
which were culture adapted more than 20 years ago (30).
Importantly, the panel of strains was not devised to include all
known alleles of each resistance-mediating gene reported here, as
it would require a very large number of strains to be tested, ren-
dering screening activities largely ineffective. More than 20 differ-
ent mutant pfcrt alleles, for instance, have been described to date
(32). We favored the selection of a relatively limited number of
strains to optimally represent the main causal mutations together
with the largest possible diversity in order to facilitate the decon-
volution of resistance signals with a manageable number of para-
site strains. A direct corollary is that additional specific strains
should be screened when a specific mode of resistance might be
suspected on the basis of the structure of a compound or a specific
activity pattern.
A limitation of our approach is that cross-resistance with arte-
misinins is not readily detectable with the current panel of P. fal-
ciparum strains, first, because none of them has been reported to
be resistant to artemisinins and, second, because the standard in
vitro IC50 determination assay using 72 h of drug exposure is not
suited to the detection of this specific resistance phenotype (45).
Consequently, it will be essential to include in the panel one or
more of the artemisinin-resistant strains recently made available
at MR4 (strains MRA-1236 to MRA-1241) and to profile the ac-
tivities of new compounds against them using the recently devel-
oped ring-stage survival assay, which is able to replicate artemis-
inin resistance in the laboratory (45, 46). Along the same line, it
would be important to determine the genotype of the strains dis-
cussed here for K13, a recently described genetic marker of arte-
misinin resistance (47). These strains were isolated either before
the introduction of artemisinins or from areas where resistance
has not yet been reported, and consequently, all are expected to be
the K13 wild type, but this awaits confirmation. Characterization
of the panel could also be reinforced by typing additional minor
genetic polymorphisms involved in resistance mechanisms as
compensatorymutations or secondary determinants, such as gch1
copy number, pfcrtmutations outside codons 72 to 76, or pfmrp1
polymorphisms (32, 48, 49).
More importantly and in order to stay as representative and
effective as possible, the composition of an optimal panel will
necessarily need to evolve with time to include strains with new
resistance mechanisms emerging in the field. The recent report of
apparent clinical resistance to piperaquine might prefigure such a
case (23). Once they are available, field-isolated and validated pip-
eraquine-resistant strains should be included in a revised test cas-
cade.
Overall, the multiple sensitive and MDR P. falciparum strains
characterized here can be used as a tool to identify cross-resistance
with known naturally occurring resistance mechanisms rapidly
and effectively. The panel can thus be used to facilitate the identi-
fication of pan-active compounds and to determine the genetic
determinants of resistance to compounds displaying cross-resis-
tance signals. By testing between 2 strains (for pan-active com-
pounds) and 5 strains (for compounds displaying a pfmdr1-me-
diated or unresolved resistance), in addition to NF54, the test
cascade presented here allows such information to be rapidly
gained and facilitates early decision making during drug develop-
ment (15, 50). An understanding of the mode of resistance to new
antimalarial compounds can also potentially inform the design of
new analogues to overcome it.
The mechanism of resistance against compounds of the 1,2,4-
oxadiazole series, presented here, could successfully be related to
pfcrt. This, in turn, guided the identification of the potential mode
of action for these compounds to be through the inhibition of
falcipain 2 in the food vacuole. Interestingly, the structure of the
series does not contain the typical pharmacophore of cysteine pro-
tease inhibitors, and the apparent disconnect between falcipain 2
inhibition and whole-cell activity may be explained by the pres-
ence of two basic amines that would allow the compounds to be
Chugh et al.
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concentrated in the acidic food vacuole by a pH gradient (51).
Further studies might investigate the morphological changes to
the parasite induced by compounds of the 1,2,4-oxadiazole series,
as falcipain inhibitors have previously been associated with im-
paired hemoglobin digestion, which was visible by light micros-
copy (52). Analogues potentially able to overcome the pfcrt-me-
diated resistance might also be synthesized and tested.
Altogether, evaluation of the 1,2,4-oxadiazole case study series
illustrates the breadth of information that can be gained by pro-
filing new antimalarial compounds with this set of P. falciparum
strains. Ultimately, the careful selection of compounds refractory
to already existing resistancemechanisms is an essential step in the
development of new antimalarial drugs, which is facilitated by the
testing strategy developed here.
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